Aubagne

Sartorius Stedim Biotech SA: Implementation of a new contract of liquidity with Kepler Cheuvreux

Tuesday, May 4, 2021 - 12:23pm

of the French Commercial Code, and the AMF decision no.

Key Points: 
  • of the French Commercial Code, and the AMF decision no.
  • As a total solutions provider, the company helps its customers to manufacture biotech medications safely, rapidly and economically.
  • Headquartered in Aubagne, France, Sartorius Stedim Biotech is quoted on the Eurolist of Euronext Paris.
  • With its own manufacturing and R&D sites in Europe, North America and Asia and an international network of sales companies, Sartorius Stedim Biotech has a global reach.

Resolutions of the Annual Shareholders' Meeting of Sartorius Stedim Biotech S.A.

Wednesday, March 24, 2021 - 2:44pm

Sartorius Stedim Biotech is a leading international partner of the biopharmaceutical industry.

Key Points: 
  • Sartorius Stedim Biotech is a leading international partner of the biopharmaceutical industry.
  • As a total solutions provider, the company helps its customers to manufacture biotech medications safely, rapidly and economically.
  • Headquartered in Aubagne, France, Sartorius Stedim Biotech is quoted on the Eurolist of Euronext Paris.
  • With its own manufacturing and R&D sites in Europe, North America and Asia and an international network of sales companies, Sartorius Stedim Biotech has a global reach.

Sartorius Stedim Biotech increases its full-year 2021 guidance

Thursday, March 18, 2021 - 7:13am

AUBAGNE, France, March 18, 2021 /PRNewswire/ -- Based on very strong order intake during the first 10 weeks of 2021 and high demand expected to continue in the further course of the year, Sartorius Stedim Biotech has raised its growth forecast for fiscal 2021.

Key Points: 
  • AUBAGNE, France, March 18, 2021 /PRNewswire/ -- Based on very strong order intake during the first 10 weeks of 2021 and high demand expected to continue in the further course of the year, Sartorius Stedim Biotech has raised its growth forecast for fiscal 2021.
  • The major part of the expected additional business is related to the coronavirus pandemic as many products of Sartorius Stedim Biotech are used for manufacturing vaccines.
  • Sartorius Stedim Biotech will publish first quarter 2021 figures as scheduled on April 21, 2021.
  • Furthermore, Sartorius Stedim Biotech reserves the right not to be responsible for the topicality, correctness, completeness or quality of the information provided.

Sartorius Stedim Biotech SA: Information on Document Availability

Thursday, February 18, 2021 - 8:01am

It contains the following information:

Key Points: 
  • It contains the following information:
    - Consolidated financial statements for the year ended December 31, 2020
    Sartorius Stedim Biotech is a leading international partner of the biopharmaceutical industry.
  • As a total solutions provider, the company helps its customers to manufacture biotech medications safely, rapidly and economically.
  • Headquartered in Aubagne, France, Sartorius Stedim Biotech is quoted on the Eurolist of Euronext Paris.
  • With its own manufacturing and R&D sites in Europe, North America and Asia and an international network of sales companies, Sartorius Stedim Biotech has a global reach.

Board of Directors of Sartorius Stedim Biotech resolves to propose dividend of 0.68 euros per share to Annual Shareholders' Meeting

Friday, February 5, 2021 - 4:52pm

AUBAGNE, France, Feb. 5, 2021 /PRNewswire/ -- The Board of Directors of Sartorius Stedim Biotech S.A. resolved at today's meeting to submit a proposal to the combined Annual General Shareholders' Meeting on March 24, 2021, to pay a dividend for fiscal 2020 of 0.68 euros per share.

Key Points: 
  • AUBAGNE, France, Feb. 5, 2021 /PRNewswire/ -- The Board of Directors of Sartorius Stedim Biotech S.A. resolved at today's meeting to submit a proposal to the combined Annual General Shareholders' Meeting on March 24, 2021, to pay a dividend for fiscal 2020 of 0.68 euros per share.
  • This press release contains forward-looking statements about the future development of the Sartorius Stedim Biotech Group.
  • Sartorius Stedim Biotech assumes no liability for updating such statements in light of new information or future events.
  • Sartorius Stedim Biotech shall not assume any liability for the correctness of this translation.

Sartorius Stedim Biotech to acquire Novasep's chromatography process equipment division

Wednesday, January 6, 2021 - 10:00am

AUBAGNE, France, Jan. 6, 2021 /PRNewswire/ -- Sartorius Stedim Biotech, a leading international partner of the biopharmaceutical industry, today announced it has entered into an agreement to acquire the chromatography process equipment division of Novasep.

Key Points: 
  • AUBAGNE, France, Jan. 6, 2021 /PRNewswire/ -- Sartorius Stedim Biotech, a leading international partner of the biopharmaceutical industry, today announced it has entered into an agreement to acquire the chromatography process equipment division of Novasep.
  • Since 2018, Novasep and Sartorius Stedim Biotech have been collaborating in the joint development of an optimized system for a membrane-based, low-pressure chromatography that processes larger molecules more productively and will be launched soon.
  • "I am pleased that we will intensify our successful collaboration with the Novasep team, soon to be under the Sartorius Stedim Biotech roof," said Dr. Ren Fber, Member of the Board of Directors of Sartorius Stedim Biotech.
  • Sartorius Stedim Biotech assumes no liability for updating such statements in light of new information or future events.

Sartorius Stedim Biotech acquires filtration expert WaterSep BioSeparations

Wednesday, December 9, 2020 - 8:40pm

AUBAGNE, France, Dec. 9, 2020 /PRNewswire/ -- Sartorius Stedim Biotech, a leading international partner of the biopharmaceutical industry, today acquired U.S.-based purification expert WaterSepBioSeparationsLLC.

Key Points: 
  • AUBAGNE, France, Dec. 9, 2020 /PRNewswire/ -- Sartorius Stedim Biotech, a leading international partner of the biopharmaceutical industry, today acquired U.S.-based purification expert WaterSepBioSeparationsLLC.
  • "I am pleased to welcome the WaterSep team to Sartorius Stedim Biotech and look forward to jointly introducing WaterSep BioSeparations innovative solutions to ourcustomers."
  • WaterSep is excited to join the Sartorius Stedim Biotech team as they continue to lead the transformation of bioprocessing to single use," said AttilaHerczeg, CEO and President of WaterSep BioSeparations.
  • Sartorius Stedim Biotech assumes no liability for updating such statements in light of new information or future events.

Sartorius Stedim Biotech closes acquisition of BIA Separations

Monday, November 2, 2020 - 5:30pm

AUBAGNE, France, Nov. 2, 2020 /PRNewswire/ -- Sartorius Stedim Biotech (SSB), a leading partner of the biopharma industry, successfully closed the acquisition of the Slovenian purification specialist BIA Separations.

Key Points: 
  • AUBAGNE, France, Nov. 2, 2020 /PRNewswire/ -- Sartorius Stedim Biotech (SSB), a leading partner of the biopharma industry, successfully closed the acquisition of the Slovenian purification specialist BIA Separations.
  • "BIA's portfolio is highly complementary to Sartorius Stedim Biotech.
  • 25 million euros in 2020 at profit margins that will be accretive to the underlying EBITDA margin of the Sartorius Stedim Biotech Group.
  • Sartorius Stedim Biotech assumes no liability for updating such statements in light of new information or future events.

Sartorius Stedim Biotech SA: Information on Document Availability

Tuesday, July 21, 2020 - 7:01am

The report on the first half 2020 results of Sartorius Stedim Biotech Group (Paris: DIM) is now available at:

Key Points: 
  • The report on the first half 2020 results of Sartorius Stedim Biotech Group (Paris: DIM) is now available at:
    It contains the following information:
    Consolidated financial statements for the period ended June 30, 2020
    Sartorius Stedim Biotech is a leading international partner of the biopharmaceutical industry.
  • As a total solutions provider, the company helps its customers to manufacture biotech medications safely, rapidly and economically.
  • Headquartered in Aubagne, France, Sartorius Stedim Biotech is quoted on the Eurolist of Euronext Paris.
  • With its own manufacturing and R&D sites in Europe, North America and Asia and an international network of sales companies, Sartorius Stedim Biotech has a global reach.

Sartorius Stedim Biotech SA: Half-year report of the liquidity contract with the stockbroker company Gilbert Dupont

Thursday, July 2, 2020 - 1:05pm

As a total solutions provider, the company helps its customers to manufacture biotech medications safely, rapidly and economically.

Key Points: 
  • As a total solutions provider, the company helps its customers to manufacture biotech medications safely, rapidly and economically.
  • Headquartered in Aubagne, France, Sartorius Stedim Biotech is quoted on the Eurolist of Euronext Paris.
  • With its own manufacturing and R&D sites in Europe, North America and Asia and an international network of sales companies, Sartorius Stedim Biotech has a global reach.
  • The Group has been annually growing by double digits on average and has been regularly expanding its portfolio by acquisitions of complementary technologies.